The Responsibility of Strong MS Treatment and Children PatientsMay 27th 2017
Brenda Banwell, MD, FAAP, FRCPC, Children's Hospital of Philadelphia's Neurology Division chief, talks about the cruciality of early diagnosing in pediatric multiple sclerosis patients, and how their best outcome is just being able to live a normal, everyday life.
Degenerative Conditions in Pediatric MS Worsened By Limited Case StudiesMay 26th 2017
Brenda Banwell, MD, FAAP, FRCPC, chief of Childrens Hospital of Philadelphia's Division of Neurology, speaks on new discoveries of pediatric MS at the annual 2017 Consortium of Multiple Sclerosis Centers (CMSC) in New Orleans.
Jeffrey Cohen, MD, Discusses New MS CriteriaMay 26th 2017
The director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic shared what's shaping the soon-to-be-released update on the most recent 2010 diagnosing criteria at the 2017 Consortium of Multiple Sclerosis Centers.
Stephen Krieger, MD, Talks Ocrelizumab in RRMS and PPMS TreatmentMay 25th 2017
Stephen Krieger, MD, an associate professor at Mount Sinai Hospital, discusses the impact that recently-approved drug ocrelizumab has on the state of multiple sclerosis care, as well as his patient-centered app that depicts the MS condition in a more accurate manner, at the 2017 Consortium of Multiple Sclerosis Centers in New Orleans.
The Hidden Role of Testosterone in Multiple SclerosisMay 24th 2017
Clyde Markowitz, MD, director of the MS Center at the University of Pennsylvania, discusses how the patterns of male-to-female ratio in MS diagnoses may be linked to hormones, and whether testosterone could be key in bettering treatment.
Interdisciplinary, Patient-centered, Comprehensive Care Necessary for MS TreatmentMay 24th 2017
At CMSC 2017, Aaron Boster, MD, neuroimmunologist for OhioHealth Neurological Clinicians, discussed why he believes there's never been a better time of opportunity for multiple sclerosis patients, and what must be improved in MS diagnosis practice.